MIF and non-small cell lung carcinoma: A novel HDAC/MIF dual-target inhibitor (6a) at a concentration of 12.5 μM promotes apoptosis by inhibiting HDAC activity and inducing histone acetylation (H3K27ac), while simultaneously blocking the MIF-CXCR7-AKT signaling pathway, thereby synergistically inhibiting the survival and proliferation of NSCLC cells (especially EGFR-mutant/TKI-resistant strains).